Docket No.

263675US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Thomas RUECKLE, et al.

SERIAL NO: FILED:

FOR:

10/520,621

GAU:

January 10, 2005

AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES

EXAMINER:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

MISSIONER FOR PATENTS ALIKANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

□ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 34,423

Surinder Sachar

Registration No. 34,423

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

	:

SERIAL NO. ATTY DOCKET NO. Form PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Modified) 10/520,621 263675US0PCT APPLICANT LIST OF REFERENCES CITED BY APPLICANT Thomas RUECKLE, et al. FILING DATE GROUP January 10, 2005 **FOREIGN PATENT DOCUMENTS** 11 **TRANSLATION** DOCUMENT DATE COUNTRY NUMBER YES NO 55-36429 03/14/80 JP. AA NO JP. 55-45648 03/31/80 AB NO 0 283 036 09/21/88 EP AC AD 02/051409 07/04/02 WO NO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) JANUSZ, John M. et al. "New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 3.7-tert-Butyl-2,3-dihydro-3,3dimethylbenzofuran Derivates as Gastrointestinal Safe Antiinflammatory and Analgesic Agents: Variations at the 5 Position", ΑE J. Med. Chem., vol. 41, no. 18, pages 3515-3529, XP002223203 1998 BRUMMOND, Kay M. et al. "Solid-Phase Synthesis of BRL 49653", J. Org. Chem., vol. 64, pages 1723-1726 AF 1999 CHA, Jin Soon et al. "Exceptionally Facile Reduction of Acid Chlorides to Aldehydes by Sodium Tri-tertbutoxyaluminohydride", J. Org. Chem., vol. 58, pages 4732-4734 AG FRASER, James D. et al. "Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28", Science, vol. 251, pages 313-316 1991 FRUMAN, David A. et al. "Phosphoinositide Kinases", Annu. Rev. Biochem., vol. 67, pages 481-507 GERARD, Craig et al. "Chemokines and Disease", Nature Immunology, vol. 2, no. 2, pages 108-115 A.I HIRSCH, Emilio et al. "Resistance to thromboembolism in PI3Kgamma-deficient mice", The FASEB Journal, vol. 15, no. 11, pages 2019-2021 AK 2001 HIRSCH, Emilio et al. "Central Role for G Protein-Coupled Phosphoinositide 3-Kinase gamma in inflammation", Science, vol. 287, no. 5455, pages 1049-1053 AL 2000 KATSO, Roy et al. "Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer", Annu. Rev. Cell Dev. Biol, vol. 17, pages 615-675 2001 LAFFARGUE, Muriel et al. "Phosphoinositide 3-Kinase gamma is an Essential Amplifier of Mast Cell Function", Immunity, AN vol. 16, no.3, pages 441-451 2002 LAWLOR, Margaret A. et al. "PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?", Journal of Cell AO Science, vol. 114, no. 16, pages 2903-2910 2001 LESLIE, Nick R. et al. "Phosphoinositide-Regulated Kinases and Phosphoinositide Phosphatases", Chem. Rev., vol. 101, no. 8, pages 2365-2380 2001 LOPEZ-ILASACA, Marco et al. "Phosphoinositide 3-Kinase gamma Is a Mediator of Gbetagamma-dependent Jun Kinase Activation", The Journal of Biological Chemistry, vol. 273, no. 5, pages 2505-2508 PANAYOTOU, George et al. "Phosphatidyl-inositol 3-Kinase: a key enzyme in diverse signalling processes", Trends in Cell Biology, vol. 2, pages 358-360 AR 1992 PARKER, Peter J. "PI 3-kinase puts GTP on the Rac", Current Biology, vol. 5, no.6, pages 577-579 AS Additional References sheet(s) attached 1995 **Date Considered** Examiner *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449		U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO	•		
(Modified) PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT		PATENT AND TRADEMARK OFFICE	263675US0PCT	1	0/520,621		
			APPLICANT				
		RENCES CITED BY APPLICANT	Thomas RUECKLE, et al.				
			FILING DATE	GROUP			
1:			January 10, 2005				
, j.			Including Author, Title, Date, Pertinent				
Ţ	АТ	PETROV, Ognyan et al. "C-Formylation of some 2(3H)-Benzazolones and 2H-1,4-Benzoxazin-3(4H)-One", Collect. Cze Chem. Commun., vol. 62, pages 494-497 1997					
	ΑU	PAGES, Francoise et al. "Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling", Nature, vo. 369, pages 327-329 1994					
	AV	RUDD, Christopher E. "Upstream-Downstream: CD28 Cosignaling Pathways and T Cell Function", Immunity, vol. 4, pages 527-534 1996					
	AW	STEPHENS, Len et al. "Roles of PI3Ks in leukocyte chemotaxis and phagocytosis", Curr. Opinion Cell Biol., vol. 14, no.2, pages 203-213 2002					
	AX	THELEN, Marcus et al. "Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucle binding protein-coupled receptor signaling in neutrophil leukocytes", Proc. Natl. Acad. Sci., vol. 91, pages 4960-4964 1994					
	AY						
	AZ	TOKER, A. "Phosphoinositides and signal transduction", Cell. Mol. Life Sci., vol. 59, no. 5, pages 761-779 2002					
	AAA	1999					
	AABI	VANHAESEBROECK, Bart et al. "Phosphoinositide 3-kinases: a conserved family of signal transducers", TIBS, vol. 22, 7, pages 267-272 1997					
	AAC	WYMANN, Matthias P. et al. "Lipids on the move: phosphoinositide 3-kinases in leukocyte function", Immunology Toda 21, no. 6, pages 260-264 2000					
	AAD	YAO, Ryoji et al. "Requirement for Phosphatidylinositol-3 Kinase in the Prevention of Apoptosis by Nerve Growth Factors Science, vol. 267, pages 2003-2005 1995					
	AAE						
	AAF						
	AAG			-			
	AAH						
	AAI						
	AAJ						
Examiner				Date Considered			
*Examiner: In	nitial if r	eference is considered, whether or no to considered. Include copy of this form	t citation is in conformance with MPEP 60s n with next communication to applicant.		tation if not in		

U.S. PCT Application Serial No.: 10/520,621 Docket No.: <u>263675US0PCT</u>

STATEMENT OF RELEVANCY

1) References <u>AA, AB, AE</u> have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
3) References <u>AC, AD, AF-AAD</u> are discussed in the specification. A copy of these references is being submitted here with.
4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.